Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Abnormal bone architecture in mice expressing MyD88 in cells of the osteoclast lineage.

Suren C, Lukashova L, Wischmann J, Wulsten D, Wildemann B, Von Eisenhart-Rothe R, Holzmann B, Mayer-Kuckuk P.

J Biol Regul Homeost Agents. 2019 Jul-Aug;33(4):1105-1111.

PMID:
31332987
2.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
3.

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.

Haas J, Würthwein C, Korporal-Kuhnke M, Viehoever A, Jarius S, Ruck T, Pfeuffer S, Meuth SG, Wildemann B.

Front Immunol. 2019 Jun 4;10:1204. doi: 10.3389/fimmu.2019.01204. eCollection 2019.

4.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.

PMID:
31034002
5.

Impact of Gentamicin-Loaded Bone Graft on Defect Healing in a Sheep Model.

Beuttel E, Bormann N, Pobloth AM, Duda GN, Wildemann B.

Materials (Basel). 2019 Apr 4;12(7). pii: E1116. doi: 10.3390/ma12071116.

6.
7.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

8.

The effect of autologous platelet rich plasma on tenocytes of the human rotator cuff.

Pauly S, Klatte-Schulz F, Stahnke K, Scheibel M, Wildemann B.

BMC Musculoskelet Disord. 2018 Nov 30;19(1):422. doi: 10.1186/s12891-018-2339-5.

9.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.

PMID:
30446966
10.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

11.

The first Japanese report on neuromyelitis optica rediscovered: acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891).

Jarius S, Wuthenow AB, Wildemann B.

J Neurol Sci. 2018 Dec 15;395:121-125. doi: 10.1016/j.jns.2018.09.005. Epub 2018 Sep 6.

PMID:
30312903
12.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
13.

7 Tesla MRI of Balo's concentric sclerosis versus multiple sclerosis lesions.

Behrens JR, Wanner J, Kuchling J, Ostendorf L, Harms L, Ruprecht K, Niendorf T, Jarius S, Wildemann B, Gieß RM, Scheel M, Bellmann-Strobl J, Wuerfel J, Paul F, Sinnecker T.

Ann Clin Transl Neurol. 2018 Jun 29;5(8):900-912. doi: 10.1002/acn3.572. eCollection 2018 Aug.

14.

Bone morphogenetic proteins - 7 and - 2 in the treatment of delayed osseous union secondary to bacterial osteitis in a rat model.

Helbig L, Omlor GW, Ivanova A, Guehring T, Sonntag R, Kretzer JP, Minkwitz S, Wildemann B, Schmidmaier G.

BMC Musculoskelet Disord. 2018 Jul 27;19(1):261. doi: 10.1186/s12891-018-2203-7.

15.

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.

Karimian-Jazi K, Wildemann B, Diem R, Schwarz D, Hielscher T, Wick W, Bendszus M, Breckwoldt MO.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 16;5(5):e480. doi: 10.1212/NXI.0000000000000480. eCollection 2018 Sep.

16.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

17.

The role of cuticular hydrocarbons in mate recognition in Drosophila suzukii.

Snellings Y, Herrera B, Wildemann B, Beelen M, Zwarts L, Wenseleers T, Callaerts P.

Sci Rep. 2018 Mar 22;8(1):4996. doi: 10.1038/s41598-018-23189-6.

18.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6. Review.

19.

Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort.

Soelberg K, Nilsson AC, Nielsen C, Jarius S, Reindl M, Wildemann B, Lillevang ST, Asgari N.

Mult Scler Relat Disord. 2018 Apr;21:97-102. doi: 10.1016/j.msard.2018.03.003. Epub 2018 Mar 7.

PMID:
29544193
20.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

21.

Different Achilles Tendon Pathologies Show Distinct Histological and Molecular Characteristics.

Klatte-Schulz F, Minkwitz S, Schmock A, Bormann N, Kurtoglu A, Tsitsilonis S, Manegold S, Wildemann B.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E404. doi: 10.3390/ijms19020404.

22.

Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures.

Jarius S, Würthwein C, Behrens JR, Wanner J, Haas J, Paul F, Wildemann B.

J Neuroinflammation. 2018 Jan 18;15(1):22. doi: 10.1186/s12974-017-1043-y.

23.

Comparative Analysis of Different Platelet Lysates and Platelet Rich Preparations to Stimulate Tendon Cell Biology: An In Vitro Study.

Klatte-Schulz F, Schmidt T, Uckert M, Scheffler S, Kalus U, Rojewski M, Schrezenmeier H, Pruss A, Wildemann B.

Int J Mol Sci. 2018 Jan 10;19(1). pii: E212. doi: 10.3390/ijms19010212.

24.

Magnetic resonance imaging findings at the first episode of acute optic neuritis.

Soelberg K, Skejoe HPB, Grauslund J, Smith TJ, Lillevang ST, Jarius S, Wildemann B, Paul F, Asgari N.

Mult Scler Relat Disord. 2018 Feb;20:30-36. doi: 10.1016/j.msard.2017.12.018. Epub 2017 Dec 25.

PMID:
29291481
25.

Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.

Ruprecht K, Wildemann B, Jarius S.

J Neurol. 2018 Feb;265(2):239-252. doi: 10.1007/s00415-017-8656-z. Epub 2017 Nov 2. Review.

PMID:
29098417
26.

Time-Dependent Alterations of MMPs, TIMPs and Tendon Structure in Human Achilles Tendons after Acute Rupture.

Minkwitz S, Schmock A, Kurtoglu A, Tsitsilonis S, Manegold S, Wildemann B, Klatte-Schulz F.

Int J Mol Sci. 2017 Oct 20;18(10). pii: E2199. doi: 10.3390/ijms18102199.

27.

Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography.

Jende JME, Hauck GH, Diem R, Weiler M, Heiland S, Wildemann B, Korporal-Kuhnke M, Wick W, Hayes JM, Pfaff J, Pham M, Bendszus M, Kollmer J.

Ann Neurol. 2017 Nov;82(5):676-685. doi: 10.1002/ana.25068. Epub 2017 Oct 26.

28.

Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.

Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, Reindl M, Jarius S.

J Neurol Sci. 2017 Oct 15;381:240-244. doi: 10.1016/j.jns.2017.08.3254. Epub 2017 Aug 31.

PMID:
28991690
29.

A population-based prospective study of optic neuritis.

Soelberg K, Jarius S, Skejoe H, Engberg H, Mehlsen JJ, Nilsson AC, Madsen JS, Reindl M, Wildemann B, Grauslund J, Kyvik KO, Smith TJ, Lillevang ST, Paul F, Weinshenker BG, Asgari N.

Mult Scler. 2017 Dec;23(14):1893-1901. doi: 10.1177/1352458517734070. Epub 2017 Oct 5.

PMID:
28980518
30.

New insights into tenocyte-immune cell interplay in an in vitro model of inflammation.

Stolk M, Klatte-Schulz F, Schmock A, Minkwitz S, Wildemann B, Seifert M.

Sci Rep. 2017 Aug 29;7(1):9801. doi: 10.1038/s41598-017-09875-x.

31.

Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.

Jarius S, König FB, Metz I, Ruprecht K, Paul F, Brück W, Wildemann B.

J Neuroinflammation. 2017 Aug 29;14(1):171. doi: 10.1186/s12974-017-0929-z.

32.

Devic's disease before Devic: On the contribution of Friedrich Albin Schanz (1863-1923).

Jarius S, Wildemann B.

J Neurol Sci. 2017 Aug 15;379:99-102. doi: 10.1016/j.jns.2017.05.044. Epub 2017 May 23.

PMID:
28716289
33.

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Gahlen A, Trampe AK, Haupeltshofer S, Ringelstein M, Aktas O, Berthele A, Wildemann B, Gold R, Jarius S, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363. eCollection 2017 Jul.

34.

From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.

Wallwitz U, Brock S, Schunck A, Wildemann B, Jarius S, Hoffmann F.

J Neuroimmunol. 2017 Aug 15;309:77-81. doi: 10.1016/j.jneuroim.2017.05.011. Epub 2017 May 22.

PMID:
28601293
35.

Failure of alemtuzumab therapy to control MOG encephalomyelitis.

Wildemann B, Jarius S, Schwarz A, Diem R, Viehöver A, Hähnel S, Reindl M, Korporal-Kuhnke M.

Neurology. 2017 Jul 11;89(2):207-209. doi: 10.1212/WNL.0000000000004087. Epub 2017 Jun 9. No abstract available.

PMID:
28600462
36.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

37.

Pavlov's Reflex before Pavlov: Early Accounts from the English, French and German Classic Literature.

Jarius S, Wildemann B.

Eur Neurol. 2017;77(5-6):322-326. doi: 10.1159/000475811. Epub 2017 May 25.

38.

A short artificial antimicrobial peptide shows potential to prevent or treat bone infections.

Bormann N, Koliszak A, Kasper S, Schoen L, Hilpert K, Volkmer R, Kikhney J, Wildemann B.

Sci Rep. 2017 May 4;7(1):1506. doi: 10.1038/s41598-017-01698-0.

39.

[Neuromyelitis optica].

Pache F, Wildemann B, Paul F, Jarius S.

Fortschr Neurol Psychiatr. 2017 Feb;85(2):e1. doi: 10.1055/s-0035-1567186. Epub 2017 Apr 5. German. No abstract available.

PMID:
28380640
40.

* Demineralized Bone Matrix as a Carrier for Bone Morphogenetic Protein-2: Burst Release Combined with Long-Term Binding and Osteoinductive Activity Evaluated In Vitro and In Vivo.

Huber E, Pobloth AM, Bormann N, Kolarczik N, Schmidt-Bleek K, Schell H, Schwabe P, Duda GN, Wildemann B.

Tissue Eng Part A. 2017 Dec;23(23-24):1321-1330. doi: 10.1089/ten.TEA.2017.0005. Epub 2017 Apr 28.

PMID:
28351338
41.

[Neuromyelitis optica].

Pache F, Wildemann B, Paul F, Jarius S.

Fortschr Neurol Psychiatr. 2017 Feb;85(2):100-114. doi: 10.1055/s-0042-124186. Epub 2017 Feb 24. Review. German.

PMID:
28235212
42.

Diagnostic criteria for Susac syndrome.

Kleffner I, Dörr J, Ringelstein M, Gross CC, Böckenfeld Y, Schwindt W, Sundermann B, Lohmann H, Wersching H, Promesberger J, von Königsmarck N, Alex A, Guthoff R, Frijns CJ, Kappelle LJ, Jarius S, Wildemann B, Aktas O, Paul F, Wiendl H, Duning T; European Susac Consortium (EuSaC).

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1287-1295. doi: 10.1136/jnnp-2016-314295. Epub 2016 Oct 25. Review.

PMID:
28103199
43.

B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis.

Schwarz A, Balint B, Korporal-Kuhnke M, Jarius S, von Engelhardt K, Fürwentsches A, Bussmann C, Ebinger F, Wildemann B, Haas J.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 15;4(1):e309. doi: 10.1212/NXI.0000000000000309. eCollection 2017 Jan.

44.

Treatment of Tibial Non-Unions - State of the Art and Future Implications.

Märdian S, Giesecke M, Haschke F, Tsitsilonis S, Wildemann B, Schwabe P.

Acta Chir Orthop Traumatol Cech. 2016;83(6):367-374. Review.

PMID:
28026731
45.

The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.

Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, Wildemann B.

J Neurol. 2017 Mar;264(3):453-466. doi: 10.1007/s00415-016-8360-4. Epub 2016 Dec 22. Review.

PMID:
28005176
46.

Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.

Breckwoldt MO, Gradl J, Hähnel S, Hielscher T, Wildemann B, Diem R, Platten M, Wick W, Heiland S, Bendszus M.

J Neurol. 2017 Feb;264(2):341-349. doi: 10.1007/s00415-016-8353-3. Epub 2016 Dec 1.

PMID:
27909801
47.

[Importance of cerebrospinal fluid diagnostics in neuropsychiatric diseases].

Tumani H, Uhr M, Wildemann B, Wick M.

Nervenarzt. 2016 Dec;87(12):1259-1260. German. No abstract available.

PMID:
27853851
48.

[Autoantibody-associated autoimmune encephalitis and cerebellitis : Clinical presentation, diagnostic work-up and treatment].

Lewerenz J, Jarius S, Wildemann B, Wandinger KP, Leypoldt F.

Nervenarzt. 2016 Dec;87(12):1293-1299. Review. German.

PMID:
27847964
49.

Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.

Haas J, Schwarz A, Korporal-Kuhnke M, Jarius S, Wildemann B.

J Neuroimmunol. 2016 Dec 15;301:53-60. doi: 10.1016/j.jneuroim.2016.10.007. Epub 2016 Nov 2.

PMID:
27836182
50.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):281.

Supplemental Content

Loading ...
Support Center